Global TRPV6 Targeted Therapy Clinical Innovation, Market Development Trends, Therapeutic Targeting Modalities & Clinical Trials Insight 2026
“Global TRPV6 Targeted Therapy Clinical Innovation, Market Development Trends, Therapeutic Targeting Modalities & Clinical Trials Insight 2026” Report Findings & Highlights:
The market for TRPV6 targeted therapies is beginning to become a distinct market within ion channel therapeutics and precision medicine. TRPV6 is a very selective calcium channel that is involved in regulating calcium transport, the integrity of the epithelium, and calcium signaling pathways. TRPV6 dysregulation has been found to be associated with cancer, inflammation, conditions involving calcium malabsorption, bone related conditions, and nephrolithiasis, among others, which makes TRPV6 an interesting drug target and an opportunity for treatment beyond just cancer.
Even though there are no approved treatments targeting TRPV6 so far, the field has progressed a lot since the initial validation stages to clinical testing stage. Various approaches are being studied for inhibition or activation of TRPV6, depending on the disease in question, using small molecules, monoclonal antibodies, peptides, and drug repositioning. With the leading compound having entered Phase II/III clinical trials in China, TRPV6 is a promising drug market at an early stage of development.
This report gives an overall evaluation of the global market for TRPV6 targeted therapies from a biological and pipeline perspective for pharmaceutical companies, biotech firms, investors, and strategic partners. In the light of increased interest in therapies targeting the various ion channel, the report highlights the existing progress and future market prospects in this sector.
Clinical Trial Insights Included In The Report
The clinical development of TRPV6 targeted therapies is at present mainly oriented towards oncology, with inhibitory effects seen in oncological disorders in which there is overexpression of this channel, especially prostate cancer and ovarian cancer. Nevertheless, accumulating preclinical and translational data is increasing interest in non-oncological disorders, including inflammatory diseases, hypocalcemia, bone disorders, and preventing the formation of kidney stones by means of selective modulation or rescue of TRPV6 activity.
The report covers the complete clinical pipeline right from the preclinical stage up to Phase I, Phase I/II, and Phase II/III stages. Special attention is paid to disease specific modulation where antagonists have been explored for oncology applications while agonists and expression enhancement strategies have been explored for disorders related to faulty calcium transport and epithelial dysfunction. The report also provides an assessment of developing trends with respect to biomarker based patient selection strategies, structural pharmacology, and targeting approaches that will impact the future of clinical development.
Major Companies Driving TRPV6 Research & Development
The landscape of TRPV6 space is presently dominated by a few biotech companies along with academic-commercial partnerships in the field of ion channels. Companies such as Coherent Biopharma, Mabqi, Soricimed Biopharma, and UniQuest are working towards the development of various technologies directed against TRPV6 in various therapeutic modalities including peptides, antibodies, small molecules, and platform technologies.
At the same time, growing structural biology insights into TRPV6 have stimulated the pharmaceutical industry's interest in rational drug design, and technological advancements in cryoelectron microscopy and modeling will facilitate the discovery of novel sites of action and optimized modulators. Strategic partnerships among biotechnology firms, academia, and drug discovery enterprises are anticipated to be key contributors to pipeline growth and translational research.
Future Outlook For TRPV6 Targeted Therapies
TRPV6 targeted therapies are anticipated to advance far beyond their current use in oncology. Growing scientific insights into TRPV6 biology have underscored the possibility of selective TRPV6 inhibition in disease states characterized by hyperactivation of the channel and excessive influx of calcium ions and activation in diseases linked to hypocalcemia or barrier function impairment of the epithelium. Further advancements in structural pharmacology, selective ligands development, and precision medicine will likely contribute to rapid discovery of new TRPV6 modulators.
As further clinical information is obtained during late phase trials, the commercial prospects of TRPV6 based therapeutics are likely to be clarified. Further success will depend upon clinical validation, use of biomarkers for patient selection, and diversification across various indications. With the help of the scientific background, insights on disease specific potential, pipeline knowledge, competitive comparison, and market assessment, this report serves as a valuable source of information about one of the promising areas of drug development via ion channels.
- Clinical Innovation & Development Trends Insight
- First TRPV6 Targeted Therapy Commercial Availability Expected By 2032
- Highest Clinical Phase Of Development: Phase II/III
- Insight On TRPV6 Targeted Therapies In Clinical Trials: > 5 Therapies
- TRPV6 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
- Therapeutic Role of TRPV6 Targeting In Various Cancer Types
- Key Drugs Initiation & Completion Year Timeline
- Competitive Landscape
The market for TRPV6 targeted therapies is beginning to become a distinct market within ion channel therapeutics and precision medicine. TRPV6 is a very selective calcium channel that is involved in regulating calcium transport, the integrity of the epithelium, and calcium signaling pathways. TRPV6 dysregulation has been found to be associated with cancer, inflammation, conditions involving calcium malabsorption, bone related conditions, and nephrolithiasis, among others, which makes TRPV6 an interesting drug target and an opportunity for treatment beyond just cancer.
Even though there are no approved treatments targeting TRPV6 so far, the field has progressed a lot since the initial validation stages to clinical testing stage. Various approaches are being studied for inhibition or activation of TRPV6, depending on the disease in question, using small molecules, monoclonal antibodies, peptides, and drug repositioning. With the leading compound having entered Phase II/III clinical trials in China, TRPV6 is a promising drug market at an early stage of development.
This report gives an overall evaluation of the global market for TRPV6 targeted therapies from a biological and pipeline perspective for pharmaceutical companies, biotech firms, investors, and strategic partners. In the light of increased interest in therapies targeting the various ion channel, the report highlights the existing progress and future market prospects in this sector.
Clinical Trial Insights Included In The Report
The clinical development of TRPV6 targeted therapies is at present mainly oriented towards oncology, with inhibitory effects seen in oncological disorders in which there is overexpression of this channel, especially prostate cancer and ovarian cancer. Nevertheless, accumulating preclinical and translational data is increasing interest in non-oncological disorders, including inflammatory diseases, hypocalcemia, bone disorders, and preventing the formation of kidney stones by means of selective modulation or rescue of TRPV6 activity.
The report covers the complete clinical pipeline right from the preclinical stage up to Phase I, Phase I/II, and Phase II/III stages. Special attention is paid to disease specific modulation where antagonists have been explored for oncology applications while agonists and expression enhancement strategies have been explored for disorders related to faulty calcium transport and epithelial dysfunction. The report also provides an assessment of developing trends with respect to biomarker based patient selection strategies, structural pharmacology, and targeting approaches that will impact the future of clinical development.
Major Companies Driving TRPV6 Research & Development
The landscape of TRPV6 space is presently dominated by a few biotech companies along with academic-commercial partnerships in the field of ion channels. Companies such as Coherent Biopharma, Mabqi, Soricimed Biopharma, and UniQuest are working towards the development of various technologies directed against TRPV6 in various therapeutic modalities including peptides, antibodies, small molecules, and platform technologies.
At the same time, growing structural biology insights into TRPV6 have stimulated the pharmaceutical industry's interest in rational drug design, and technological advancements in cryoelectron microscopy and modeling will facilitate the discovery of novel sites of action and optimized modulators. Strategic partnerships among biotechnology firms, academia, and drug discovery enterprises are anticipated to be key contributors to pipeline growth and translational research.
Future Outlook For TRPV6 Targeted Therapies
TRPV6 targeted therapies are anticipated to advance far beyond their current use in oncology. Growing scientific insights into TRPV6 biology have underscored the possibility of selective TRPV6 inhibition in disease states characterized by hyperactivation of the channel and excessive influx of calcium ions and activation in diseases linked to hypocalcemia or barrier function impairment of the epithelium. Further advancements in structural pharmacology, selective ligands development, and precision medicine will likely contribute to rapid discovery of new TRPV6 modulators.
As further clinical information is obtained during late phase trials, the commercial prospects of TRPV6 based therapeutics are likely to be clarified. Further success will depend upon clinical validation, use of biomarkers for patient selection, and diversification across various indications. With the help of the scientific background, insights on disease specific potential, pipeline knowledge, competitive comparison, and market assessment, this report serves as a valuable source of information about one of the promising areas of drug development via ion channels.
1. RESEARCH METHODOLOGY
2. TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNELS & TRPV FAMILY OVERVIEW
2.1 Overview Of The Transient Receptor Potential (TRP) Channel Family
2.2 Overview Of The TRPV (Vanilloid) Channel Subfamily
2.3 Introduction To TRPV6: Biology, Physiological Functions & Clinical Significance
3. TRPV6 BIOLOGY, FUNCTION & PATHOPHYSIOLOGY
3.1 Structural Architecture & Calcium Selectivity Of TRPV6
3.2 Tissue Distribution, Expression Profile & Cellular Localization Of TRPV6
3.3 Physiological Roles Of TRPV6 In Calcium Homeostasis & Organ Function
3.4 TRPV6 Mediated Calcium Signalling In Health & Disease
4. PHARMACOLOGICAL MODULATION & THERAPEUTIC TARGETING OF TRPV6
4.1 Ligand Mediated Modulation Of TRPV6 Activity
4.1.1 TRPV6 Antagonism - Mechanisms & Therapeutic Rationale
4.1.2 TRPV6 Agonism - Mechanisms & Therapeutic Rationale
4.2 Therapeutic Targeting Modalities For TRPV6
4.2.1 Small Molecule Modulators
4.2.2 Antibody Based Therapeutic Targeting
4.2.3 Peptide Based Therapeutic Approaches
4.2.4 Drug Repurposing Strategies
4.3 Structural Pharmacology & Structure Based Drug Design Of TRPV6
4.3.1 Pore Targeting & Allosteric Binding Sites In TRPV6
4.3.2 Lipid Binding, Channel Gating & Allosteric Regulation Of TRPV6
5. TRPV6 TARGETED THERAPIES IN CANCER
5.1 Prostate Cancer
5.2 Breast Cancer
5.3 Pancreatic Cancer
5.4 Ovarian Cancer
5.5 Esophageal Cancer
6. TRPV6 TARGETED THERAPIES IN NON CANCER DISORDERS
6.1 Inflammation
6.2 Calcium Malabsorption Disorders
6.3 Bone Diseases
6.4 Kidney Stones
7. GLOBAL TRPV6 TARGETED THERAPIES CLINICAL TRIALS OVERVIEW
7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
8. GLOBAL TRPV6 TARGETED THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase II/III
9. GLOBAL TRPV6 TARGETED THERAPY MARKET SCENARIO
9.1 Current Market Trends
9.2 Future Market Opportunities
10. GLOBAL TRPV6 TARGETED THERAPY MARKET DYNAMICS
10.1 Drivers & Opportunities
10.2 Challenges & Solutions
11. COMPETITIVE LANDSCAPE
11.1 Coherent Biopharma
11.2 Mabqi
11.3 Soricimed Biopharma
11.4 UniQuest
2. TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNELS & TRPV FAMILY OVERVIEW
2.1 Overview Of The Transient Receptor Potential (TRP) Channel Family
2.2 Overview Of The TRPV (Vanilloid) Channel Subfamily
2.3 Introduction To TRPV6: Biology, Physiological Functions & Clinical Significance
3. TRPV6 BIOLOGY, FUNCTION & PATHOPHYSIOLOGY
3.1 Structural Architecture & Calcium Selectivity Of TRPV6
3.2 Tissue Distribution, Expression Profile & Cellular Localization Of TRPV6
3.3 Physiological Roles Of TRPV6 In Calcium Homeostasis & Organ Function
3.4 TRPV6 Mediated Calcium Signalling In Health & Disease
4. PHARMACOLOGICAL MODULATION & THERAPEUTIC TARGETING OF TRPV6
4.1 Ligand Mediated Modulation Of TRPV6 Activity
4.1.1 TRPV6 Antagonism - Mechanisms & Therapeutic Rationale
4.1.2 TRPV6 Agonism - Mechanisms & Therapeutic Rationale
4.2 Therapeutic Targeting Modalities For TRPV6
4.2.1 Small Molecule Modulators
4.2.2 Antibody Based Therapeutic Targeting
4.2.3 Peptide Based Therapeutic Approaches
4.2.4 Drug Repurposing Strategies
4.3 Structural Pharmacology & Structure Based Drug Design Of TRPV6
4.3.1 Pore Targeting & Allosteric Binding Sites In TRPV6
4.3.2 Lipid Binding, Channel Gating & Allosteric Regulation Of TRPV6
5. TRPV6 TARGETED THERAPIES IN CANCER
5.1 Prostate Cancer
5.2 Breast Cancer
5.3 Pancreatic Cancer
5.4 Ovarian Cancer
5.5 Esophageal Cancer
6. TRPV6 TARGETED THERAPIES IN NON CANCER DISORDERS
6.1 Inflammation
6.2 Calcium Malabsorption Disorders
6.3 Bone Diseases
6.4 Kidney Stones
7. GLOBAL TRPV6 TARGETED THERAPIES CLINICAL TRIALS OVERVIEW
7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
8. GLOBAL TRPV6 TARGETED THERAPIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase II/III
9. GLOBAL TRPV6 TARGETED THERAPY MARKET SCENARIO
9.1 Current Market Trends
9.2 Future Market Opportunities
10. GLOBAL TRPV6 TARGETED THERAPY MARKET DYNAMICS
10.1 Drivers & Opportunities
10.2 Challenges & Solutions
11. COMPETITIVE LANDSCAPE
11.1 Coherent Biopharma
11.2 Mabqi
11.3 Soricimed Biopharma
11.4 UniQuest
LIST OF TABLES
Table 2-1: Classification & Functions of TRP Channel Subfamilies
Table 2-2: ThermoTRPV v/s Calcium-selective TRPV Channels
Table 2-3: Tissue Distribution Of TRPV Channels
Table 2-4: Physiological Distribution Of TRPV6
Table 2-5: Comparison Of Physiological v/s Pathological TRPV6
Table 3-1: Structural Components Of TRPV6
Table 3-2: Diseases Associated With Altered TRPV6 Function
Table 4-1: Mechanistic Actions Of TRPV6 Antagonists
Table 4-2: Key Conceptual Differences: TRPV6 Agonism vs Antagonism
Table 4-3: Small Molecule TRPV6 Targeting - Advantages
Table 4-4: Peptide Based TRPV6 Inhibitors - Advantages
Table 4-5: Advantages of Drug Repurposing For TRPV6
Table 4-6: Pore block vs Allosteric inhibition In TRPV6
Table 6-1: Inflammatory Disorders - Role Of TRPV6
Table 6-2: Role Of TRPV6 In Calcium Malabsorption Disorders
Table 6-3: Bone Diseases - Therapeutic Potential Of TRPV6
Table 6-4: TRPV6 & Kidney Stone Disease
Table 2-1: Classification & Functions of TRP Channel Subfamilies
Table 2-2: ThermoTRPV v/s Calcium-selective TRPV Channels
Table 2-3: Tissue Distribution Of TRPV Channels
Table 2-4: Physiological Distribution Of TRPV6
Table 2-5: Comparison Of Physiological v/s Pathological TRPV6
Table 3-1: Structural Components Of TRPV6
Table 3-2: Diseases Associated With Altered TRPV6 Function
Table 4-1: Mechanistic Actions Of TRPV6 Antagonists
Table 4-2: Key Conceptual Differences: TRPV6 Agonism vs Antagonism
Table 4-3: Small Molecule TRPV6 Targeting - Advantages
Table 4-4: Peptide Based TRPV6 Inhibitors - Advantages
Table 4-5: Advantages of Drug Repurposing For TRPV6
Table 4-6: Pore block vs Allosteric inhibition In TRPV6
Table 6-1: Inflammatory Disorders - Role Of TRPV6
Table 6-2: Role Of TRPV6 In Calcium Malabsorption Disorders
Table 6-3: Bone Diseases - Therapeutic Potential Of TRPV6
Table 6-4: TRPV6 & Kidney Stone Disease
LIST OF FIGURES
Figure 2-1: TRP Channel Family Overview
Figure 2-2: General Structure Of TRP Channels
Figure 2-3: Classification Of Mammalian TRP Channels
Figure 2-4: TRP Channels Activation Mechanisms
Figure 2-5: Functional Classification Of TRPV Subfamily
Figure 2-6: Functional Diversity Of TRPV1–TRPV6
Figure 2-7: Historical Timeline of TRPV6 Research
Figure 2-8: Physiological Roles of TRPV6 in Different Organs
Figure 2-9: Regulation Of TRPV6 Expression
Figure 2-10: Consequences of TRPV6 Dysfunction
Figure 2-11: From Calcium Transporter To Cancer Target
Figure 2-12: Why TRPV6 IS An Attractive Drug Target
Figure 3-1: Structural Basis Of TRPV6 Function
Figure 3-2: Regulation Of TRPV6 By Lipids & Calmodulin
Figure 3-3: Structural Basis Of Pharmacological Inhibition By 2-APB
Figure 3-4: Organ Distribution Of TRPV6 Expression
Figure 3-5: Physiological Functions of TRPV6
Figure 3-6: TRPV6 In Intestinal Calcium Absorption
Figure 3-7: Role Of TRPV6 In Placental Calcium Transport
Figure 3-8: TRPV6 In Male Reproductive Physiology
Figure 3-9: TRPV6 In Bone Homeostasis
Figure 3-10: TRPV6 In Epidermal Differentiation
Figure 3-11: Consequences of TRPV6 Loss- & Gain-of-Function
Figure 4-1: Overview Of TRPV6 Modulation
Figure 4-2: Core Principle Of TRPV6 Antagonism
Figure 4-3: TRPV6-Calcium-NFAT Oncogenic Axis & Its Inhibition
Figure 4-4: Antagonism Effects On Cancer Cell Fate
Figure 4-5: Core Principle Of TRPV6 Agonism
Figure 4-6: Vitamin D–TRPV6 Regulatory Axis & Agonism Concept
Figure 4-7: Safety Window Concept In TRPV6 Agonism
Figure 4-8: Small Molecule TRPV6 Inhibition Strategy
Figure 4-9: Binding Sites Of TRPV6 Small Molecule Inhibitors
Figure 4-10: Mechanism Of TRPV6-Targeting Antibody MQI-201
Figure 4-11: Mechanism Of Antitumor Action Of TRPV6-Targeting Peptides
Figure 4-12: Therapeutic Applications Of TRPV6-Targeting Peptides
Figure 4-13: Concept Of Drug Repurposing For TRPV6 Targeted Cancer Therapy
Figure 4-14: Allosteric Inhibition Of TRPV6 By Econazole
Figure 4-15: Pore blockade vs Allosteric inhibition - Mechanism
Figure 4-16: PIP?-Dependent Gating Mechanism
Figure 4-17: Lipid Occupancy Vs Drug Displacement Mechanism
Figure 5-1: Crosstalk With Androgen Signaling + SOCE
Figure 5-2: Hormonal Regulation & Drug Modulation Of TRPV6
Figure 5-3: CBP-1008-01 Phase 1 (NCT04740398) Study – Initiation & Completion Year
Figure 5-4: TRPV6 & Chemoresistance
Figure 6-1: Context-Dependent Role Of TRPV6 In Inflammatory Diseases
Figure 6-2: Inflammatory Disease - Therapeutic Strategy Based On TRPV6 Activity
Figure 6-3: Physiological Role Of TRPV6 In Systemic Calcium Homeostasis
Figure 6-4: Calcium Malabsorption Disorders - Therapeutic Strategies Targeting TRPV6
Figure 6-5: Consequences Of TRPV6 Deficiency In Calcium Malabsorption (Secondary Hyperparathyroidism)
Figure 6-6: Central Role Of TRPV6 In Bone Homeostasis
Figure 6-7: Therapeutic Strategies Targeting TRPV6 in Bone Diseases
Figure 6-8: TRPV6 In Calcium Homeostasis & Kidney Stone Formation
Figure 6-9: Mechanisms Of Hypercalciuria Associated With TRPV6
Figure 6-10: Genetic Variants Of TRPV6 & Risk Of Nephrolithiasis
Figure 6-11: Current vs Future Management Of Nephrolithiasis
Figure 7-1: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Phase, 2026
Figure 7-2: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Country, 2026
Figure 7-3: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Company , 2026
Figure 7-4: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Indication, 2026
Figure 7-5: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Priority Status , 2026
Figure 9-1: Global TRPV6 Targeting Therapy - Future Market Opportunities
Figure 10-1: Global TRPV6 Targeting Therapy - Drivers & Opportunities
Figure 10-2: Global TRPV6 Targeting Therapy - Challenges & strategic Solutions
Figure 2-1: TRP Channel Family Overview
Figure 2-2: General Structure Of TRP Channels
Figure 2-3: Classification Of Mammalian TRP Channels
Figure 2-4: TRP Channels Activation Mechanisms
Figure 2-5: Functional Classification Of TRPV Subfamily
Figure 2-6: Functional Diversity Of TRPV1–TRPV6
Figure 2-7: Historical Timeline of TRPV6 Research
Figure 2-8: Physiological Roles of TRPV6 in Different Organs
Figure 2-9: Regulation Of TRPV6 Expression
Figure 2-10: Consequences of TRPV6 Dysfunction
Figure 2-11: From Calcium Transporter To Cancer Target
Figure 2-12: Why TRPV6 IS An Attractive Drug Target
Figure 3-1: Structural Basis Of TRPV6 Function
Figure 3-2: Regulation Of TRPV6 By Lipids & Calmodulin
Figure 3-3: Structural Basis Of Pharmacological Inhibition By 2-APB
Figure 3-4: Organ Distribution Of TRPV6 Expression
Figure 3-5: Physiological Functions of TRPV6
Figure 3-6: TRPV6 In Intestinal Calcium Absorption
Figure 3-7: Role Of TRPV6 In Placental Calcium Transport
Figure 3-8: TRPV6 In Male Reproductive Physiology
Figure 3-9: TRPV6 In Bone Homeostasis
Figure 3-10: TRPV6 In Epidermal Differentiation
Figure 3-11: Consequences of TRPV6 Loss- & Gain-of-Function
Figure 4-1: Overview Of TRPV6 Modulation
Figure 4-2: Core Principle Of TRPV6 Antagonism
Figure 4-3: TRPV6-Calcium-NFAT Oncogenic Axis & Its Inhibition
Figure 4-4: Antagonism Effects On Cancer Cell Fate
Figure 4-5: Core Principle Of TRPV6 Agonism
Figure 4-6: Vitamin D–TRPV6 Regulatory Axis & Agonism Concept
Figure 4-7: Safety Window Concept In TRPV6 Agonism
Figure 4-8: Small Molecule TRPV6 Inhibition Strategy
Figure 4-9: Binding Sites Of TRPV6 Small Molecule Inhibitors
Figure 4-10: Mechanism Of TRPV6-Targeting Antibody MQI-201
Figure 4-11: Mechanism Of Antitumor Action Of TRPV6-Targeting Peptides
Figure 4-12: Therapeutic Applications Of TRPV6-Targeting Peptides
Figure 4-13: Concept Of Drug Repurposing For TRPV6 Targeted Cancer Therapy
Figure 4-14: Allosteric Inhibition Of TRPV6 By Econazole
Figure 4-15: Pore blockade vs Allosteric inhibition - Mechanism
Figure 4-16: PIP?-Dependent Gating Mechanism
Figure 4-17: Lipid Occupancy Vs Drug Displacement Mechanism
Figure 5-1: Crosstalk With Androgen Signaling + SOCE
Figure 5-2: Hormonal Regulation & Drug Modulation Of TRPV6
Figure 5-3: CBP-1008-01 Phase 1 (NCT04740398) Study – Initiation & Completion Year
Figure 5-4: TRPV6 & Chemoresistance
Figure 6-1: Context-Dependent Role Of TRPV6 In Inflammatory Diseases
Figure 6-2: Inflammatory Disease - Therapeutic Strategy Based On TRPV6 Activity
Figure 6-3: Physiological Role Of TRPV6 In Systemic Calcium Homeostasis
Figure 6-4: Calcium Malabsorption Disorders - Therapeutic Strategies Targeting TRPV6
Figure 6-5: Consequences Of TRPV6 Deficiency In Calcium Malabsorption (Secondary Hyperparathyroidism)
Figure 6-6: Central Role Of TRPV6 In Bone Homeostasis
Figure 6-7: Therapeutic Strategies Targeting TRPV6 in Bone Diseases
Figure 6-8: TRPV6 In Calcium Homeostasis & Kidney Stone Formation
Figure 6-9: Mechanisms Of Hypercalciuria Associated With TRPV6
Figure 6-10: Genetic Variants Of TRPV6 & Risk Of Nephrolithiasis
Figure 6-11: Current vs Future Management Of Nephrolithiasis
Figure 7-1: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Phase, 2026
Figure 7-2: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Country, 2026
Figure 7-3: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Company , 2026
Figure 7-4: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Indication, 2026
Figure 7-5: Global – Number Of TRPV6 Inhibitors In Clinical Trials By Priority Status , 2026
Figure 9-1: Global TRPV6 Targeting Therapy - Future Market Opportunities
Figure 10-1: Global TRPV6 Targeting Therapy - Drivers & Opportunities
Figure 10-2: Global TRPV6 Targeting Therapy - Challenges & strategic Solutions
